Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF. Gennari A, et al. Among authors: orlandini c. Clin Breast Cancer. 2002 Dec;3(5):346-52. doi: 10.3816/CBC.2002.n.038. Clin Breast Cancer. 2002. PMID: 12533265 Clinical Trial.
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer.
Gennari A, De Tursi M, Carella C, Ricevuto E, Orlandini C, Frassoldati A, Conte P, Bruzzi P, Iacobelli S. Gennari A, et al. Among authors: orlandini c. Breast Cancer Res Treat. 2009 May;115(1):131-6. doi: 10.1007/s10549-008-0048-8. Epub 2008 Sep 13. Breast Cancer Res Treat. 2009. PMID: 18791821 Clinical Trial.
New combinations with epirubicin in advanced breast cancer.
Conte P, Gennari A, Landucci E, Guarneri V, Donati S, Salvadori B, Bengala C, Orlandini C. Conte P, et al. Among authors: orlandini c. Oncology (Williston Park). 2001 May;15(5 Suppl 7):24-7. Oncology (Williston Park). 2001. PMID: 11396361 Free article. Review.
Role of epirubicin in advanced breast cancer.
Conte PF, Gennari A, Landucci E, Orlandini C. Conte PF, et al. Among authors: orlandini c. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S46-51. doi: 10.3816/cbc.2000.s.009. Clin Breast Cancer. 2000. PMID: 11970749 Review.
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crinò L, Conte PF. Cappuzzo F, et al. Among authors: orlandini c. Br J Cancer. 2004 Jan 12;90(1):31-5. doi: 10.1038/sj.bjc.6601518. Br J Cancer. 2004. PMID: 14710202 Free PMC article. Clinical Trial.
75 results